Interaction of liposomes with BLM is confirmed to consist of two stages. The first stage is a semi-fusion of liposomes with BLM. On this stage the bilayer in a contact area is formed of one liposome monolayer and another one of BLM. The second stage is inclusion of liposome bilayers into BLM; it occurs some tens of minutes after the first one. It occurs either by fusion or incorporation. The fusion to incorporation ratio increases with temperature. Liposomes are incorporated in BLM asymmetrically: the contact area of the liposome bilayer is always smaller than the free one.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Modification of Liposomal Properties by an Engineered Gemini Surfactant.
Langmuir
January 2025
Department of Physics, Virginia Tech, Blacksburg, Virginia 24061, United States.
Lipid membranes form the primary structure of cell membranes and serve as configurable interfaces across numerous applications including biosensing technologies, antifungal treatments, and therapeutic platforms. Therefore, the modification of lipid membranes by additives has important consequences in both biological processes and practical applications. In this study, we investigated a nicotinic-acid-based gemini surfactant (NAGS) as a chemically tunable molecular additive for modulating the structure and phase behavior of liposomal membranes.
View Article and Find Full Text PDFCholesterol Attenuates the Pore-Forming Capacity of CARC-Containing Amphipathic Peptides.
Int J Mol Sci
January 2025
A. N. Belozersky Institute of Physico-Chemical Biology, M. V. Lomonosov Moscow State University, Leninskie Gory 1, Bld. 40, Moscow 119992, Russia.
Artificial peptides P4, A1 and A4 are homologous to amphipathic α-helical fragments of the influenza virus M1 protein. P4 and A4 contain the cholesterol recognition sequence CARC, which is absent in A1. As shown previously, P4 and A4 but not A1 have cytotoxic effects on some eukaryotic and bacterial cells.
View Article and Find Full Text PDFNanotherapeutics for Meningitis: Enhancing Drug Delivery Across the Blood-Brain Barrier.
Biomimetics (Basel)
January 2025
GloNeuro, Sector 107, Vishwakarma Road, Noida 201301, Uttar Pradesh, India.
Meningitis is the acute or chronic inflammation of the protective membranes, surrounding the brain and spinal cord, and this inflammatory process spreads throughout the subarachnoid space. The traditional drug delivery methods pose a disadvantage in limiting the capacity of crossing the blood-brain barrier (BBB) to reach the central nervous system (CNS). Hence, it is imperative to develop novel approaches that can overcome these constraints and offer efficient therapy for meningitis.
View Article and Find Full Text PDFRegulation of macrophage-mediated osteogenesis by kaempferol liposomes in trauma-induced heterotopic ossification.
Int J Pharm
January 2025
Key Laboratory of Bone Tissue Regeneration and Digital Medicine, Xuzhou Medical University, Xuzhou 221006 Jiangsu, China; Department of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006 Jiangsu, China. Electronic address:
Background: Heterotopic ossification (HO) is characterized by abnormal bone formation outside the skeleton following injury or inherited disease, leading to limb dysfunction and neurological deficits. Current treatment options for HO are largely ineffective.
Methods: A network pharmacological analysis was conducted to identify the active ingredients and protein targets in Astragalus and Cinnamon Twig Five-Substance Decoction (ACTFSD) on HO.
Targeted therapy for glioblastoma utilizing hyaluronic acid-engineered liposomes for adriamycin delivery.
Nanotechnology
January 2025
Nanjing Medical University, Department of Neurosurgery, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Nanjing, 210029, CHINA.
Glioblastoma (GBM) is a malignant tumor with highly heterogeneous and invasive characteristics leading to a poor prognosis. The CD44 molecule, which is highly expressed in GBM, has emerged as a highly sought-after biological marker. Therapeutic strategies targeting the cell membrane protein CD44 have emerged, demonstrating novel therapeutic potential.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!